



## Novel Nanoparticle-Based Treatment and Imaging Modalities

Guest Editors:

**Dr. Oleh Taratula**

Department of Pharmaceutical  
Sciences, College of Pharmacy,  
Oregon State University,  
Portland, OR, USA

**Dr. Olena Taratula**

Department of Pharmaceutical  
Sciences, College of Pharmacy,  
Oregon State University,  
Portland, OR, USA

Deadline for manuscript  
submissions:

**closed (20 May 2022)**

### Message from the Guest Editors

Over the last twenty years, nanomaterials have been widely used in cancer research. Numerous reports suggest that nanoparticles have the potential to improve conventional therapeutic (e.g., chemotherapy) and imaging (e.g., MRI) modalities for cancer detection and treatment. Nanomaterials allow further development of novel experimental treatment and imaging strategies, including photothermal therapy, magnetic hyperthermia, and photoacoustic imaging. In addition, though to a lesser extent, nanoparticle-based imaging and treatment modalities have frequently been explored for other nonmalignant diseases, such as pulmonary fibrosis, AIDS, muscular dystrophy, etc. The results of this research suggest that some fundamental principles of cancer nanomedicine could potentially be used for the development of novel nanoparticle-based strategies for treatment and imaging of other disorders. In this Special Issue, we invite authors to report their recently developed nanoparticle-based modalities for diagnosis and/or treatment of various disease states. We also welcome reviewer articles with expert opinions and perspectives in the nanomedicine field.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma